News
1h
Zacks Investment Research on MSNAmgen Looks to Take Share of Booming Obesity Space: Will It Succeed?Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the ...
A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...
Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help her stop binge drinking.
By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer. Each week the mother of two injects herself ...
Plus: Why Krispy Kreme left McDonald's, Boeing's latest woes, the potential Shell-BP merger, Bumble's stumble, Nvidia's cloud ...
Amy Spencer, a Missouri-based pioneer, navigates the unregulated gray market of obesity medicines. Utilizing drugs like Eli Lilly's Zepbound under the radar, Spencer reduces her weight and costs ...
The Vanguard Growth ETF ( VUG 0.85%) doesn't just beat the market -- it demolishes it. A $10,000 investment at its 2004 ...
If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...
Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.
It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results